Form 4: Abbott VP & Controller Boosts ABT Stake with Stock Awards

Abbott Laboratories' Vice President and Controller, John A. McCoy Jr., reported the acquisition of performance-based restricted stock and employee stock options.

Summary

• John A. McCoy Jr., Vice President and Controller of Abbott Laboratories (ABT), reported transactions on February 24, 2026.
• Acquired 5,373 common shares without par value as a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program.
• This restricted stock award has a 3-year term, with no more than one-third vesting annually upon Abbott reaching a minimum return on equity target.
• Acquired 22,151 employee stock options with an exercise price of $114.6, granted under the Abbott Laboratories 2017 Incentive Stock Program.
• The stock options become exercisable in annual increments: 7,383 shares on February 24, 2027; 7,384 shares on February 24, 2028; and 7,384 shares on February 24, 2029.
• The options have an expiration date of February 23, 2036.
• Following these transactions, McCoy directly beneficially owns 26,355 common shares and 22,151 derivative securities (options).
• An additional 58 common shares are indirectly owned through the Abbott Laboratories Stock Retirement Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, reflecting management's continued alignment with shareholder interests through performance-based compensation and increased insider ownership.

Positives

• The acquisition of performance-based restricted stock aligns management's interests directly with shareholder value creation, as vesting is tied to a minimum return on equity target.
• The grant of employee stock options provides a long-term incentive for the Vice President and Controller to contribute to the company's growth and stock performance.
• Increased insider ownership, even through compensation, can signal management's confidence in the company's future prospects.

Future Outlook

The performance-based nature of the restricted stock award, tied to a minimum return on equity target, implies a focus on future financial performance. The multi-year vesting schedule for both restricted stock and options indicates a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that the granting of performance-based restricted stock and employee stock options is a standard practice in executive compensation across various industries. This type of compensation structure is designed to align the interests of executives with those of shareholders by tying a portion of their remuneration to the company's long-term performance and stock price appreciation. For Abbott Laboratories, these grants reinforce a commitment to performance-driven incentives for key personnel.

Comparison to Industry Standards

• The use of performance-based restricted stock awards, with vesting contingent on specific financial targets like Return on Equity (ROE), is a common and well-regarded practice in executive compensation, aligning with best practices seen in companies like Johnson & Johnson (JNJ) and Medtronic (MDT).
• Multi-year vesting schedules for stock options, such as the 3-year annual increment vesting seen here, are typical for long-term incentive plans across the S&P 500, promoting executive retention and sustained performance.
• The grant of options under an established incentive stock program (Abbott Laboratories 2017 Incentive Stock Program) is standard and comparable to similar programs at peer companies in the healthcare and medical device sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive, as executive compensation is tied to company performance metrics (Return on Equity) and stock price appreciation, aligning management incentives with shareholder returns.
• Employees: The incentive program may foster a performance-driven culture, potentially benefiting employees through overall company success.

Next Steps

• The restricted stock award will vest over a 3-year term, with no more than one-third vesting annually upon Abbott reaching a minimum return on equity target.
• The employee stock options will become exercisable in annual increments on February 24, 2027, February 24, 2028, and February 24, 2029.

Key Dates

Recommendation

This Form 4 reports routine executive compensation in the form of performance-based restricted stock and stock options. While it represents an increase in insider ownership and aligns management incentives with shareholder interests, it is a standard compensation event and not typically a standalone catalyst for a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance for investors already confident in Abbott's long-term strategy and performance.

Keywords

Abbott Laboratories, ABT, Form 4, Insider Transaction, Restricted Stock, Stock Options, Executive Compensation, Corporate Governance, Performance-Based Award, Beneficial Ownership